Levosimendan cardioprotection reduces the metabolic response during temporary regional coronary occlusion in an open chest pig model

Acta Anaesthesiologica Scandinavica

Volumn 51, Issue 1, 2007, Pages 86-93

  Metzsch, C ^a,b   Liao, Q ^a   Steen, S ^a   Algotsson, L ^a  

^a LUND UNIVERSITY   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Calcium sensitizers; Cardioprotection; Levosimendan; Microdialysis; Myocardial ischemia; Myocardial metabolism; Myocardial performance

Indexed keywords

GLUCOSE; LACTIC ACID; LEVOSIMENDAN; PYRUVIC ACID;

ANALYSIS OF VARIANCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERY OCCLUSION; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY CIRCUMFLEX BRANCH; FEMALE; HEART INFARCTION; HEART MUSCLE CONTRACTILITY; HEART MUSCLE ISCHEMIA; HEART OUTPUT; HEART PROTECTION; HEMODYNAMICS; MALE; METABOLISM; MICRODIALYSIS; NONHUMAN; PRIORITY JOURNAL; REPERFUSION; SYSTEMIC VASCULAR RESISTANCE;

ANIMALS; CARDIAC OUTPUT; CARDIOTONIC AGENTS; CORONARY CIRCULATION; GLUCOSE; HYDRAZONES; INFUSIONS, INTRAVENOUS; LACTIC ACID; MICRODIALYSIS; MYOCARDIAL CONTRACTION; MYOCARDIAL ISCHEMIA; MYOCARDIAL REPERFUSION; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; PYRIDAZINES; PYRUVIC ACID; SUS SCROFA;

EID: 33845694924     PISSN: 00015172     EISSN: 13996576     Source Type: Journal    
DOI: 10.1111/j.1399-6576.2006.01162.x     Document Type: Article

References (27)

1. Toller WG, Stranz C. Levosimendan, a new inotropic and vasodilator agent. Anesthesiology 2006; 104: 556-69.
2. Papp Z, Csapo K, Pollesello P, Haikala H, Edes I. Pharmacological mechanisms contributing to the clinical efficacy of levosimendan. Cardiovasc Drug Rev 2005; 23: 71-98.
3. Moiseyev VS, Poder P, Andrejevs N, Ruda MY, Golikov AP, Lazebnik LB et al. Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN). Eur Heart J 2002; 23: 1422-32.
4. Delle Karth G, Buberl A, Geppert A, Neunteufl T, Huelsmann M, Kopp C et al. Hemodynamic effects of a continuous infusion of levosimendan in critically ill patients with cardiogenic shock requiring catecholamines. Acta Anaesthesiol Scand 2003; 47: 1251-6.
5. Sonntag S, Sundberg S, Lehtonen LA, Kleber FX. The calcium sensitizer levosimendan improves the function of stunned myocardium after percutaneous transluminal coronary angioplasty in acute myocardial ischemia. J Am Coll Cardiol 2004; 43: 2177-82.
6. Lilleberg J, Nieminen MS, Akkila J, Heikkilä L, Kuitunen A, Lehtonen L et al. Effects of a new calcium sensitizer, levosimendan, on haemodynamics, coronary blood flow and myocardial substrate utilization early after coronary artery bypass grafting. Eur Heart J 1998; 19: 660-8.
7. Nijhawan N, Nicolosi AC, Montgomery MW, Aggarwal A, Pagel PS, Warltier DC. Levosimendan enhances cardiac performance after cardiopulmonary bypass: a prospective, randomised placebo-controlled trial. J Cardiovasc Pharmacol 1999; 34: 219-28.
8. Kersten JR, Montgomery MW,.Pagel PS, Warltier DC. Levosimendan, a new positive inotropic drug, decreases myocardial infarct size via activation of K (ATP) channels. Anesth Analg 2000; 90: 5-11.
9. Tritapepe L, De Santis V, Vitale D, Santulli M, Morelli A, Nofroni I et al. Preconditioning effects of levosimendan in coronary artery bypass grafting - a pilot study. Br J Anaesth 2006; 96: 694-700.
10. Muller M. Science, medicine, and the future: microdialysis. BMJ 2002; 324: 588-91.
11. Metzsch C, Liao Q, Steen S, Algotsson A. Myocardial glycerol release, arrhythmias and hemodynamic instability during regional ischemia-reperfusion in an open chest pig model. Acta Anaesthesiol Scand 2006; 50: 99-107.
12. Nieminen MS, Akkila J, Hasenfuss G, Kleber FX, Lehtonen LA, Mitrovic V et al. Hemodynamic and neurohumeral effects of continuous infusion of levosimendan in patients with congestive heart failure. J Am Coll Cardiol 2000; 36: 1903-12.
13. Slawsky MT, Colucci WS, Gottlieb SS, Greenberg BH, Haeusslein E, Hare J et al. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Study investigators. Circulation 2000; 102: 2222-7.
14. Du Toit EF, Muller CA, McCarthy J, Opie LH. Levosimendan: effects of a calcium sensitizer on function and arrhythmias and cyclic nucleotide levels during ischemia/reperfusion in the Langendorff-perfused guinea pig heart. J Pharmacol Exp Ther 1999; 290: 505-14.
15. du Toit E, Hofmann D, McCarthy J, Pineda C. Effect of levosimendan on myocardial contractility, coronary and peripheral blood flow, and arrhytmias during coronary artery ligation and reperfusion in the in vivo pig model. Heart 2001; 86: 81-7.
16. Tassani P, Schad H, Heimisch W, Bernhard-Abt A, Ettner U, Mendler N et al. Effect of the calcium sensitizer levosimendan on the performance of ischaemic myocardium in anaesthetised pigs. Cardiovasc Drugs Ther 2002; 16: 435-41.
17. Rump AF, Acar D, Rosen R, Klaus W. Functional and antiischaemic effects of the phosphodiesterase inhibitor levosimendan in isolated rabbit hearts. Pharmacol Toxicol 1994; 74: 244-8.
18. Kopustinskiene DM, Pollesello P, Saris NE. Potassium-specific effects of levosimendan on heart mitochondria. Biochem Pharmacol 2004; 68: 807-12.
19. Gross GJ, Peart JN. KATP channels and myocardial preconditioning: an update. Am J Physiol Heart Circ Physiol 2003; 285: H921-30.
20. Obal D, Dettwiler S, Favoccia C, Scharbatke H, Preckel B, Schlack W. The influence of mitochondrial KATP-channels in the cardioprotection of preconditioning and postconditioning by sevoflurane in the rat in vivo. Anesth Analg 2005; 101: 1252-60.
21. De Hert SG, Van der Linden PJ, Cromheecke S, Meeus R, Nelis A, Van Reeth V et al. Cardioprotective properties of sevoflurane in patients undergoing coronary surgery with cardiopulmonary bypass are related to the modalities of its administration. Anesthesiology 2004; 101: 299-310.
22. van Bilsen M, van der Vusse GJ, Willemsen PH, Coumans WA, Roemen TH, Reneman RS. Lipid alterations in isolated, working rat hearts during ischemia and reperfusion: its relations to myocardial damage. Circ Res 1989; 64: 304-14.
23. de Groot MJ, Coumans WA, Willemsen PH, van der Vusse GJ. Substrate-induced changes in the lipid content of ischemic and reperfused myocardium. Its relation to hemodynamic recovery. Circ Res 1993; 72: 176-86.
24. de Groot MJ, de Jong YF, Coumans WA., van der Vusse GJ. The hydrolysis of glycerol-3-phosphate into glycerol in cardiac tissue: possible consequences for the validity of glycerol release as a measure of lipolysis. Pflugers Arch 1994; 427: 96-101.
25. Clausen T, Alves OL, Reinert M, Doppenberg E, Zauner A, Bullock R. Association between elevated brain tissue glycerol levels and poor outcome following severe traumatic brain injury. J Neurosurg 2005; 103: 233-8.
26. Peerdeman SM, Girbes AR, Polderman KH, Vandertop WP. Changes in cerebral interstitial glycerol concentration in head-injured patients; correlation with secondary events. Intensive Care Med 2003; 29: 1825-8.
27. Marsch SC, Dalmas S, Philbin DM, Ryder WA, Foex P. Myocardial ischemia and reperfusion are associated with an increased stiffness of remote nonischemic myocardium. Anesth Analg 1996; 82: 695-701.